Metabolite Identification and Profiling
Assessing a drug candidate’s metabolic profile early in the discovery process offers insight into its metabolic clearance pathways in both pre-clinical species and humans. IQVIA Laboratories global bioanalytical and ADME laboratory network offers a range of liquid chromatography/ mass spectrometry services to support discovery and development metabolite identification and profiling.
Specific capabilities using high-resolution mass spectrometry (HRMS) include:
- Metabolite profiling and identification using liver microsomes or hepatocytes, as well as novel hepatocyte co-culture models for profiling slowly metabolized drug candidates
- Exploratory profiling using unlabeled drug in preclinical and human clinical samples
- Radio-profiling of both preclinical and human clinical samples
- Reactive intermediate screens evaluating glutathione/cyanide trapping drug candidates (microsomes)
ADME Assays & Metabolite Profiling
To explore how IQVIA Laboratories can partner to characterize metabolites in your study:
A full range of bioanalytical services, including metabolic stability, enzyme identification, metabolite identification, metabolite absorption, metabolite stability assays, and drug-drug interaction assessments - ranging from highly automated screens to definitive studies that enable regulatory submission.